CN1472314A - 艾滋病病毒o型株的一个免疫学表位及其应用 - Google Patents
艾滋病病毒o型株的一个免疫学表位及其应用 Download PDFInfo
- Publication number
- CN1472314A CN1472314A CNA021253730A CN02125373A CN1472314A CN 1472314 A CN1472314 A CN 1472314A CN A021253730 A CNA021253730 A CN A021253730A CN 02125373 A CN02125373 A CN 02125373A CN 1472314 A CN1472314 A CN 1472314A
- Authority
- CN
- China
- Prior art keywords
- epi
- virus
- hiv
- aids virus
- immunology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title claims description 20
- 230000036039 immunity Effects 0.000 title description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 15
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 7
- 210000004408 hybridoma Anatomy 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229960002989 glutamic acid Drugs 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000001900 immune effect Effects 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 description 8
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 241000700605 Viruses Species 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了艾滋病病毒O型株的一个免疫学表位及其应用。本发明的目的是提供艾滋病病毒O型株的一个新的免疫学表位，它包括氮末端为天门冬氨酸，碳末端为谷氨酸的两个相邻氨基酸残基。该两个氨基酸残基组成的表位的氮端通常连接的氨基酸残基为亮氨酸；碳端通常连接的氨基酸残基为色氨酸，这时该免疫学表位的氨基酸残基序列为LDEW。在该序列的基础上，通常氮端连接的氨基酸残基为谷氨酸，碳端连接的氨基酸残基为丙氨酸，这时该免疫学表位的氨基酸残基序列为ELDEWA。该表位可用于HIV－1病毒O型株鉴别和诊断的靶位点，也可以作为治疗药物的靶位点。
Description
技术领域
本发明涉及艾滋病病毒O型株的一个免疫学表位及其应用。
背景技术
获得性免疫缺陷综合症，又称艾滋病，是由人类免疫缺陷病毒I型(HIV-1)引起的一种免疫性疾病，目前尚无彻底治愈的有效药物，也没有疫苗可以预防。免疫缺陷病毒的高变异性一直是HIV疫苗和药物设计中的难题。
最近国外抗艾滋病药物临床研究结果证明，在被动免疫治疗中，组合使用针对HIV-1膜蛋白gp160(膜蛋白gp120及跨膜蛋白gp41的前体蛋白)上的几个特定中和表位的中和抗体(其中包括ELDKWA表位特异性的单克隆抗体2F5)，能抑制HIV-1病毒的粘膜传染以及母婴传播，并能清除血液中的HIV-1病毒(Nature Medicine 1999，5：204；Nature Medicine 2000，6：200；Nature Medicine 1999，5：211)；人免疫缺陷病毒(HIV-1)跨膜蛋白gp41上的主要中和表位ELDKWA的表位特异性单克隆抗体能够体外抑制多种HIV-1病毒株感染靶细胞(J.Virology 1993，67：6642；AIDS Res.HumanRetroviruses 1994，10：1651；AIDS 1996，10：587)。研究证明，HIV-1能够通过中和表位的限制性变异逃脱中和抗体的中和作用(Immunity 10，431-438，1999)。ELDKWA是公认的重要的HIV-1中和表位，该表位的保守性很强，但在D或K位点的某些限制性变异，能够使病毒逃脱单抗的中和作用。
发明内容
本发明的目的是提供艾滋病病毒O型株的一个新的免疫学表位。
艾滋病病毒O型株的一个免疫学表位，包括氮末端为天门冬氨酸，碳末端为谷氨酸的两个相邻氨基酸残基。
所述免疫学表位的氮端通常连接的氨基酸残基为亮氨酸；碳端通常连接的氨基酸残基为色氨酸，这时该免疫学表位的氨基酸残基序列为LDEW。在该序列的基础上，通常氮端连接的氨基酸残基为谷氨酸，碳端连接的氨基酸残基为丙氨酸，这时该免疫学表位的氨基酸残基序列为ELDEWA。
发明人通过对HIV数据库(http：//hiv-web.lanl.gov)的检索发现，所有HIV-1病毒O型株的跨膜蛋白gp41均带有ELDEWA表位(如表1所示)，而其它HIV-1病毒亚型不带有此表位，进一步证实ELDEWA是HIV-1病毒O型株的特有表位，可用于HIV-1病毒O型株鉴别和诊断的靶位点，也可以作为治疗药物的靶位点。
表1：HIV-1病毒O型株带有特征性的ELDEWA表位
| 登录号 | 序列 | 氨基酸残基的序号 | |
| 1 | AF009033 | LELDEWAS | 668-675 |
| 2 | AF407418 | LELDEWAS | 675-682 |
| 3 | AJ302646 | LELDEWAS | 680-687 |
| 4 | AJ302647 | LELDEWAS | 669-676 |
| 5 | L20571 | LELDEWAS | 674-681 |
| 6 | L20587 | LELDEWAS | 660-667 |
| 7 | NC_002787 | LELDEWAS | 680-687 |
| 8 | U82990 | LELDEWAS | 658-665 |
| 9 | U82991 | LELDEWAS | 670-677 |
| 10 | U82992 | LELDEWAS | 668-675 |
| 11 | U82993 | LELDEWAS | 669-676 |
| 12 | X96522 | LELDEWAS | 674-681 |
| 13 | X96526 | LELDEWAS | 677-684 |
本发明的第二个目的是提供能够与本发明艾滋病病毒O型株的免疫学表位专一结合的单克隆抗体。
利用杂交瘤技术，发明人研制出了一株能稳定分泌ELDEWA表位特异性单克隆抗体的小鼠杂交瘤细胞系14D9(鼠单克隆抗体14D9亚型：IgG1)。
小鼠杂交瘤细胞系14D9已于2002年06月27日保藏于中国微生物菌种保藏管理委员会普通微生物中心(简称CGMCC)，保藏号为CGMCC №0753。
小鼠杂交瘤细胞系14D9产生的单克隆抗体14D9能够特异性识别HIV-1病毒O型株跨膜蛋白gp41特有的ELDEWA-表位，而不识别其它HIV-1病毒亚型所携带ELDKWA-、ELDKWA-、ELNKWA-和ELEKWA-表位。
下面结合具体实施例对本发明做进一步说明。
附图说明
图1为本发明单克隆抗体与带有不同表位的重组、可溶性gp41融合蛋白反应后的电泳图。
具体实施方式
实施例1、鼠类来源的杂交瘤细胞系14D9的制备过程：
1、人工合成一条含有HIV-1 O型株跨膜蛋白gp41特有的ELDEWA-表位的表位多肽，该表位多肽含有4次重复的ELDEWA-免疫学表位，其氨基酸残基序列为：CELDEWAGELDEWAGELDEWAGELDEWA；
2、利用MBS(m-maleimidobenzoyl-N-hydroxy succinimide ester)将上述表位多肽与载体蛋白BSA耦联；
3、将上述耦联物与福氏佐剂混合(两种物质的重量比为，耦联物∶福氏佐剂＝1∶1)免疫Balb/c小鼠，每两周免疫一次。首次使用完全福氏佐剂，以后使用不完全福氏佐剂。每次免疫抗原剂量为：含10微克表位多肽的耦联物/次/只，共免疫3次；
4、将免疫后的小鼠脾细胞与小鼠骨髓瘤细胞采用常规细胞融合技术融合，并制备杂交瘤，从杂交瘤细胞中筛选出能分泌ELDEWA-表位特异性单克隆抗体的杂交瘤；
5、克隆杂交瘤，获得能分泌ELDEWA-表位特异性单克隆抗体的克隆杂交瘤细胞系14D9。
实施例2、本发明抗体对HIV-1病毒O型株ELDEWA-表位的特异性识别
将杂交瘤细胞系14D9分泌的单克隆抗体与带有不同表位的重组、可溶性gp41融合蛋白进行温浴反应，结果如图1所示，从图中的结果可以看出，杂交瘤细胞系14D9分泌的单克隆抗体对HIV-1病毒O型株ELDEWA-表位具有特异性识别，图中，A：分子量蛋白；B：本发明单克隆抗体识别带有ELDEWA表位的rsgp41(GST-rsgp41ELDEWA)〔42KD〕；C：本发明单克隆抗体不识别带有ELDKWA表位的rsgp41(GST-rsgp41ELDKWA)；D：本发明单克隆抗体不识别GST；E：本发明单克隆抗体识别含有ELDEWA表位的GST-ELDEWA(26KD)。
Claims (8)
1、艾滋病病毒O型株的一个免疫学表位，包括氮末端为天门冬氨酸，碳末端为谷氨酸的两个相邻氨基酸残基。
2、根据权利要求1所述的艾滋病病毒O型株的一个免疫学表位，其特征在于：所述免疫学表位的氨基酸残基序列为LDEW。
3、根据权利要求2所述的艾滋病病毒O型株的一个免疫学表位，其特征在于：所述免疫学表位的氨基酸残基序列为ELDEWA。
4、与权利要求1-3中任意一项所述艾滋病病毒O型株的免疫学表位专一结合的单克隆抗体。
5、由保藏号为CGMCC №0753的杂交瘤细胞系14D9产生的与艾滋病病毒O型株抗原专一结合的单克隆抗体。
6、鼠类来源的杂交瘤细胞系14D9，CGMCC №0753。
7、权利要求1-3中任意一项所述的免疫学表位在鉴别、诊断HIV-1病毒O型株中的应用。
8、权利要求1-3中任意一项所述的免疫学表位作为治疗药物靶位点的应用。
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021253730A CN1472314A (zh) | 2002-07-29 | 2002-07-29 | 艾滋病病毒o型株的一个免疫学表位及其应用 |
| PCT/CN2002/000552 WO2004011490A1 (fr) | 2002-07-29 | 2002-08-09 | Epitope immunologique de la souche vih type o et ses utilisations |
| AU2002325467A AU2002325467A1 (en) | 2002-07-29 | 2002-08-09 | A immounlogical epitope of the hiv strain type o and the uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021253730A CN1472314A (zh) | 2002-07-29 | 2002-07-29 | 艾滋病病毒o型株的一个免疫学表位及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1472314A true CN1472314A (zh) | 2004-02-04 |
Family
ID=30121235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021253730A Pending CN1472314A (zh) | 2002-07-29 | 2002-07-29 | 艾滋病病毒o型株的一个免疫学表位及其应用 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1472314A (zh) |
| AU (1) | AU2002325467A1 (zh) |
| WO (1) | WO2004011490A1 (zh) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459060A (en) * | 1989-08-24 | 1995-10-17 | Bioclonetics Incorporated | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) |
| GB9005829D0 (en) * | 1990-03-15 | 1990-05-09 | Proteus Biotech Ltd | Synthetic polypeptides |
| EP0702693A1 (en) * | 1993-06-09 | 1996-03-27 | Connaught Laboratories Limited | Tandem synthetic hiv-1 peptides |
-
2002
- 2002-07-29 CN CNA021253730A patent/CN1472314A/zh active Pending
- 2002-08-09 AU AU2002325467A patent/AU2002325467A1/en not_active Abandoned
- 2002-08-09 WO PCT/CN2002/000552 patent/WO2004011490A1/zh not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004011490A1 (fr) | 2004-02-05 |
| AU2002325467A1 (en) | 2004-02-16 |
| AU2002325467A8 (en) | 2004-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beddows et al. | Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 | |
| Ahlers et al. | Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. | |
| Bost et al. | Individuals infected with HIV possess antibodies against IL-2. | |
| AT398080B (de) | Immortalisierte zellinie, verfahren zu ihrer herstellung und verfahren zur herstellung von monoklonalen antikörpern sowie diagnoseverfahren und -mittel | |
| JPH02160800A (ja) | ヒト免疫不全ウイルス（ＨＩＶ）ｅｎｖ‐コードペプチド | |
| US6132721A (en) | Non-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same | |
| EP0492560A2 (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of HIV-1, and related peptides | |
| CN100366631C (zh) | IgG Fc/HIV-gp120/C3d 融合蛋白质 | |
| US6241986B1 (en) | Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV | |
| KR930702509A (ko) | 사람 면역결핍 바이러스(hiv)면역치료제 | |
| CN1165344C (zh) | 用于催化水解HIVgp120的组合物及其制备方法和用途 | |
| JPH05503851A (ja) | 中和および／またはａｄｃｃ仲介モノクローナルｈｉｖ抗体 | |
| CN1238499C (zh) | 艾滋病病毒0型株的一种抗体及其生产细胞系与应用 | |
| US6200575B1 (en) | Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them | |
| CN1472314A (zh) | 艾滋病病毒o型株的一个免疫学表位及其应用 | |
| McKeating et al. | Immunogenicity of full length and truncated forms of the human immunodeficiency virus type I envelope glycoprotein | |
| WO2003022879B1 (en) | Peptides mimicking a cryptic epitope of gp41 hiv-1 and antibodies directed against them | |
| Lockey et al. | Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees | |
| CN1172717C (zh) | 一种治疗艾滋病的药物及其制备方法 | |
| DE69433057T2 (de) | Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus | |
| DE69233271T2 (de) | Therapeutischer- und präventivimpfstoff gegen hiv | |
| CN1226046C (zh) | 来自逆转录病毒调节蛋白的无毒免疫原、抗体、其制备方法和含有它们的药物组合物 | |
| EP0950063A1 (en) | Multiple branch peptide constructions | |
| Schwander et al. | Phase I/II vaccination study of recombinant peptide F46 corresponding to the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP) Ficoll | |
| REEVES et al. | Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |